BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Lavor CBH, Viana Júnior AB, Medeiros FDC. Polycystic Ovary Syndrome and Metabolic Syndrome: Clinical and Laboratory Findings and Non-Alcoholic Fatty Liver Disease Assessed by Elastography. Rev Bras Ginecol Obstet 2022;44:287-94. [PMID: 35576937 DOI: 10.1055/s-0041-1741032] [Reference Citation Analysis]
2 Kristensen H, Kimer N, Møller S. Indications and methods for measuring portal hypertension in cirrhosis. Scand J Gastroenterol 2022;:1-9. [PMID: 35514215 DOI: 10.1080/00365521.2022.2065889] [Reference Citation Analysis]
3 Somers N, Vandekerckhove E, Geerts A, Degroote H, Lefere S, Devisscher L, Meuris L, Callewaert N, Van Vlierberghe H, Verhelst X. Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. Acta Clin Belg 2022;:1-7. [PMID: 35505274 DOI: 10.1080/17843286.2022.2072110] [Reference Citation Analysis]
4 Welman CJ, Saunders J, Zelesco M, Abbott S, Boardman G, Ayonrinde OT. Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation. J Med Imaging Radiat Oncol 2022. [PMID: 35466506 DOI: 10.1111/1754-9485.13412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim HY, Kwon S, Um W, Shin S, Kim CH, Park JH, Kim BS. Functional Extracellular Vesicles for Regenerative Medicine. Small 2022;:e2106569. [PMID: 35322545 DOI: 10.1002/smll.202106569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Godfrey TM, Villavicencio EA, Barra K, Sanderson PR, Shea K, Sun X, Garcia DO. Advancing Liver Cancer Prevention for American Indian Populations in Arizona: An Integrative Review. Int J Environ Res Public Health 2022;19:3268. [PMID: 35328956 DOI: 10.3390/ijerph19063268] [Reference Citation Analysis]
7 Moreno-Vedia J, Rosales R, Ozcariz E, Llop D, Lahuerta M, Benavent M, Rodríguez-Calvo R, Plana N, Pedragosa A, Masana L, Castro A, Ibarretxe D, Girona J. Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:775677. [PMID: 35082753 DOI: 10.3389/fendo.2021.775677] [Reference Citation Analysis]
8 Ding S, Yang W, Sun X, Guo Y, Zhao G, Yang J, Zhang L, Lv G, Kim KG. Computed Tomography-Based Radiomic Analysis for Preoperatively Predicting the Macrovesicular Steatosis Grade in Cadaveric Donor Liver Transplantation. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/2491023] [Reference Citation Analysis]
9 Karhan AN, Hizarcioglu-Gulsen H, Gumus E, Akçören Z, Demir H, Saltik-Temizel İN, Orhan D, Özen H. Distinctive Features of Hepatic Steatosis in Children: Is It Primary or Secondary to Inborn Errors of Metabolism? Pediatr Gastroenterol Hepatol Nutr 2021;24:518-27. [PMID: 34796096 DOI: 10.5223/pghn.2021.24.6.518] [Reference Citation Analysis]
10 Cao R, Zhang S, Li J, Zhang J, Zhao Y, Jiao P, Wang C, Guo Z. Chinese Herbal Medicine-Induced Rapid Liver Cirrhosis: A Case Report. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.118934] [Reference Citation Analysis]
11 Lai J, Jiang S, Shuai L, Zhang Y, Xia R, Chen Q, Bai L. Comparison of the biological and functional characteristics of mesenchymal stem cells from intrahepatic and identical bone marrow. Stem Cell Res 2021;55:102477. [PMID: 34343826 DOI: 10.1016/j.scr.2021.102477] [Reference Citation Analysis]
12 Yang A, Nguyen M, Ju I, Brancatisano A, Ryan B, van der Poorten D. Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery. Sci Rep 2021;11:14006. [PMID: 34234198 DOI: 10.1038/s41598-021-93294-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Dai X, Zeng Y, Zhang H, Gu Z, Gong Q, Luo K. Advances on Nanomedicines for Diagnosis and Theranostics of Hepatic Fibrosis. Adv NanoBio Res 2021;1:2000091. [DOI: 10.1002/anbr.202000091] [Reference Citation Analysis]
14 Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines 2021;9:660. [PMID: 34201309 DOI: 10.3390/biomedicines9060660] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Virarkar M, Morani AC, Taggart MW, Bhosale P. Liver Fibrosis Assessment. Semin Ultrasound CT MR 2021;42:381-9. [PMID: 34130850 DOI: 10.1053/j.sult.2021.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Stahlschmidt FL, Tafarel JR, Menini-Stahlschmidt CM, Baena CP. Hepatorenal index for grading liver steatosis with concomitant fibrosis. PLoS One 2021;16:e0246837. [PMID: 33577616 DOI: 10.1371/journal.pone.0246837] [Reference Citation Analysis]
17 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
18 Moore SC, Mazzilli KM, Sampson JN, Matthews CE, Carter BD, Playdon MC, Wang Y, Stevens VL. A Metabolomics Analysis of Postmenopausal Breast Cancer Risk in the Cancer Prevention Study II. Metabolites 2021;11:95. [PMID: 33578791 DOI: 10.3390/metabo11020095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang Z, Wen H, Peng B, Weng J, Zeng F. HFD-induced TRAF6 upregulation promotes liver cholesterol accumulation and fatty liver development via EZH2-mediated miR-429/PPARα axis. Mol Ther Nucleic Acids 2021;24:711-27. [PMID: 33996254 DOI: 10.1016/j.omtn.2021.01.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876 [PMID: 32550761 DOI: 10.3748/wjg.v26.i21.2864] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Chaim FDM, Pascoal LB, Chaim FHM, Palma BB, Damázio TA, da Costa LBE, Carvalho R, Cazzo E, Gestic MA, Utrini MP, Milanski M, Chaim EA, Leal RF. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep 2020;10:8496. [PMID: 32444690 DOI: 10.1038/s41598-020-65556-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Lu Y, Wang Q, Yu L, Yin X, Yang H, Xu X, Xia Y, Luo Y, Peng Y, Yu Q, Chen Z, Yu J, Lai M, Wu N, Pan XB, Zheng X. Revision of serum ALT upper limits of normal facilitates assessment of mild liver injury in obese children with non-alcoholic fatty liver disease. J Clin Lab Anal 2020;34:e23285. [PMID: 32267017 DOI: 10.1002/jcla.23285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
23 Park JH, Choi IS, Han KD, Park H, Kim KH, Kim JS. Association Between Fatty Liver Index and Risk of Breast Cancer: A Nationwide Population-Based Study. Clin Breast Cancer 2020;20:e450-7. [PMID: 32192863 DOI: 10.1016/j.clbc.2020.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Takakusagi S, Takagi H, Yokoyama Y, Marubashi K, Kizawa K, Kosone T, Sato K, Kakizaki S, Uraoka T. Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis. Clin J Gastroenterol 2020;13:896-901. [PMID: 32065362 DOI: 10.1007/s12328-020-01103-w] [Reference Citation Analysis]
25 Huang X, Wang L, Meng M, Zhang S, Pham TTH, Jiang L, Chen L, Li Y, Zhou X, Qin L, Wu X, Zou C, Huang R. Extract of Averrhoacarambola L. (Oxalidaceae) roots ameliorates carbon tetrachloride-induced hepatic fibrosis in rats. Biomedicine & Pharmacotherapy 2020;121:109516. [DOI: 10.1016/j.biopha.2019.109516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Al-Sulaiti H, Diboun I, Agha MV, Mohamed FFS, Atkin S, Dömling AS, Elrayess MA, Mazloum NA. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J Transl Med 2019;17:348. [PMID: 31640727 DOI: 10.1186/s12967-019-2096-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
27 Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Papageorgiou MV, Fragopoulou E, Kontogianni MD. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr 2018;120:164-75. [PMID: 29947322 DOI: 10.1017/S000711451800137X] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
28 Al-Khabori M, Daar S, Al-Busafi SA, Al-Dhuhli H, Alumairi AA, Hassan M, Al-Rahbi S, Al-Ajmi U. Noninvasive assessment and risk factors of liver fibrosis in patients with thalassemia major using shear wave elastography. Hematology. 2019;24:183-188. [PMID: 30453843 DOI: 10.1080/10245332.2018.1540518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Walraven M, Hinz B. Therapeutic approaches to control tissue repair and fibrosis: Extracellular matrix as a game changer. Matrix Biology 2018;71-72:205-24. [DOI: 10.1016/j.matbio.2018.02.020] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 22.0] [Reference Citation Analysis]
30 Akar T. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C? Rev Assoc Med Bras (1992) 2018;64:224-9. [PMID: 29641775 DOI: 10.1590/1806-9282.64.03.224] [Reference Citation Analysis]
31 Banzato T, Bonsembiante F, Aresu L, Gelain M, Burti S, Zotti A. Use of transfer learning to detect diffuse degenerative hepatic diseases from ultrasound images in dogs: A methodological study. The Veterinary Journal 2018;233:35-40. [DOI: 10.1016/j.tvjl.2017.12.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
32 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology 2018;67:549-59. [PMID: 28892558 DOI: 10.1002/hep.29514] [Cited by in Crossref: 304] [Cited by in F6Publishing: 303] [Article Influence: 76.0] [Reference Citation Analysis]
33 Sun K, Lin D, Li F, Qi Y, Feng W, Yan L, Chen C, Ren M, Liu D. Fatty liver index, albuminuria and the association with chronic kidney disease: a population-based study in China. BMJ Open 2018;8:e019097. [PMID: 29382678 DOI: 10.1136/bmjopen-2017-019097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
34 Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018;53:819-26. [PMID: 29318378 DOI: 10.1007/s00535-017-1425-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 18.5] [Reference Citation Analysis]
35 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2017;. [PMID: 28892558 DOI: 10.1002/hep.29514.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Nishikawa H, Nishimura T, Enomoto H, Iwata Y, Ishii A, Miyamoto Y, Ishii N, Yuri Y, Takata R, Hasegawa K, Nakano C, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Nishiguchi S, Iijima H. Impact of Virtual Touch Quantification in Acoustic Radiation Force Impulse for Skeletal Muscle Mass Loss in Chronic Liver Diseases. Nutrients 2017;9:E620. [PMID: 28621757 DOI: 10.3390/nu9060620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]